Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00332917 · ClinicalTrials.gov registry record · Phase 3
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
A Phase 3 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 224
- Enrollment target
NCT00332917 is a Phase 3 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 224 participants.
The verdict
NCT00332917, a Phase 3 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 224 participants
- Enrollment target
Study Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Interventions
- DRUG Pardoprunox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00332917
The ClinicalTrials.gov registry entry for NCT00332917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pardoprunox is the first listed.
NCT00332917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00332917 about?
NCT00332917 is a clinical study titled "An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients". This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
What is the current status of trial NCT00332917?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 224 participants. The study started on 2007-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00332917?
The interventions under investigation include: Pardoprunox (DRUG).
Who is sponsoring clinical trial NCT00332917?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.